Cited by 893Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerCell death mechanisms and regulation

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

Targeting mutant p53 for efficient cancer therapy

Bykov, Vladimir J. N., Eriksson, Sofi E., Bianchi, Julie, Wiman, Klas G.·2018·Nature Reviews Cancer

DOI 10.1038/nrc.2017.109

Open this paper in CoChat — free account

Abstract

The tumour suppressor gene TP53 is the most frequently mutated gene in cancer. Wild-type p53 can suppress tumour development by multiple pathways. However, mutation of TP53 and the resultant inactivation of p53 allow evasion of tumour cell death and rapid tumour progression. The high frequency of TP53 mutation in tumours has prompted efforts to restore normal function of mutant p53 and thereby trigger tumour cell death and tumour elimination. Small molecules that can reactivate missense-mutant p53 protein have been identified by different strategies, and two compounds are being tested in clinical trials. Novel approaches for targeting TP53 nonsense mutations are also underway. This Review discusses recent progress in pharmacological reactivation of mutant p53 and highlights problems and promises with these strategies.

Integrity signals

Registry

Crossref · 10.1038/nrc.2017.109

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

1 retracted

RETRACTED: Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity
Baradaran‐Heravi, A., Niesser, J., Balgi, A. D., Choi, K., Zimmerman, C., South, A. P., Anderson, H. J., Strynadka, N. C. J., Bally, M. B., & Roberge, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620982114 · Cited by 52
Retracted
The Protein Data Bank
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,671
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398

Show all 159 references

Research works printed but not linked: 1

Shi, H., Calvez, F. L., Olivier, M. & Hainaut, P. in 25 years of p53 research ( eds Hainaut, P., Wiman, K. G. ) 293–319 (Springer, 2005).

Sorted by citations

Items 601–700 of 893

Electrochemical analysis of proteins important in cancer: Behavior of anterior gradient receptors, p53 protein and their complexes at charged surfaces
Ostatná, V., Černocká, H., Galicová, T., & Hasoň, S. (2023) · Current Opinion in Electrochemistry · doi:10.1016/j.coelec.2023.101269 · Cited by 6
Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy
Lei, K., Li, J., Tu, Z., Gong, C., Liu, J., Luo, M. H., Ai, W., Wu, L., Li, Y., Zhou, Z., et al. (2024) · Theranostics · doi:10.7150/thno.98574 · Cited by 6
Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease
de Korte, D., & Hoekstra, M. (2025) · Biomolecules · doi:10.3390/biom15020185 · Cited by 6
“One of the most important transcription factors and tumor suppressors is the protein p53 [31]. p53 responds to a variety of stress signals and strictly supervises numerous cellular processes, including senescence, DNA repair, cell cycle arrest, and apoptosis.”
A carrier-free DNA nanoplatform for efficient three-in-one tumor therapy in vivo
Wang, H., Lu, X., Fan, J., Yang, C., Zhu, H., Liu, J., & Ding, B. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102734 · Cited by 6
Chemoenzymatic synthesis of a cholesterol- g -poly(amine- co -ester) carrier for p53 gene delivery to inhibit the proliferation and migration of tumor cells
Dong, M., Chen, J. C., Yang, J., Jiang, W., Han, H., Li, Q., & Yang, Y. (2018) · New Journal of Chemistry · doi:10.1039/c8nj02574f · Cited by 6
Interferon‐stimulated gene 15 enters posttranslational modifications of p53
Wang, Y., Ding, Q., Lu, Y., Cao, S., Liu, Q., & Zhang, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27347 · Cited by 6
MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells
Phoa, A., Recasens, A., Gurgis, F., Betts, T. A., Menezes, S. V., Chau, D., Nordfors, K., Haapasalo, J. A., Haapasalo, H. K., Johns, T. G., et al. (2020) · Cancers · doi:10.3390/cancers12030654 · Cited by 6
“These findings are highly relevant since p53 mutations occur in over 50% of all cancers [44].”
BackgroundInfluential
Characterization of TGFβ-associated molecular features and drug responses in gastrointestinal adenocarcinoma
Zhang, Q., Liu, F., Qin, L., Liao, Z., Song, J., Liang, H., Chen, X., Zhang, Z., & Zhang, B. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01869-4 · Cited by 8
Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
Milne, J. V., Zhang, B. Z., Fujihara, K. M., Dawar, S., Phillips, W. A., & Clemons, N. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-83979-3 · Cited by 6
Patterns of immune infiltration in gastric cancer and their clinical significance
Jin, Y., Tao, L., Jin, S., Jin, S., & Cai, W. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab054 · Cited by 6
Repair or perish – the role of p53 protein in a cell’s life
Kulesza, M., Dansonka‐Mieszkowska, A., & Pieńkowska‐Grela, B. (2019) · Nowotwory Journal of Oncology · doi:10.5603/njo.2019.0031 · Cited by 8
“Another molecule tested in the first phase of clinical trials – in gynecological cancer, head and neck cancer – is COTI-2, which functions as a chelator for zinc ions [104].”
Background
An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma
Chen, G., Wu, J., Su, Z., Wang, L., Chen, X., Zhong, X., Wang, D., Wang, J., & Shao, L. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220204140925 · Cited by 6
N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer
Nie, X., & Tan, J. (2022) · Hereditas · doi:10.1186/s41065-022-00222-3 · Cited by 6
Integrated characterization and validation of the prognostic significance of microRNA-200s in colorectal cancer
Peng, Q., Cheng, M. Y., Li, T., Chen, X., Shen, Y., Zhu, Y., & Xu, B. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1142-1 · Cited by 6
Δ133p53/FLp53 Predicts Poor Clinical Outcome in Esophageal Squamous Cell Carcinoma
Tu, Q., Gong, H., Yuan, C., Liu, G., Huang, J., Li, Z., & Luo, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s263559 · Cited by 6
Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregationPreprint
Zhao, L., Punga, T., & Sanyal, S. (2025) · eLife · doi:10.7554/elife.106469 · Cited by 6
Inhibition of platin-induced BCL2 increase overcomes chemoresistance in squamous cell carcinoma of the head and neck through resensitization to cell death
Becker, A., Klauk, F., Freitag, T., Strüder, D., Schneider, B., Zimpfer, A., & Maletzki, C. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102308 · Cited by 5
“Given that TP53 mutations (a) occur in ~ 72 % of HNSCC cases with enrichment in the HPV neg group, (b) confer cisplatin resistance, (c) are currently undruggable [31,32], and (d) can co-occur with HRAS mutations, venetoclax represents a realistic treat-ment option for a subset of HNSCC patients.”
CircTP53 /USP10/p53 signaling Axis as a Novel Regulator of Progression and Prognosis of Head and Neck Squamous Cell Carcinoma
Wang, Y., Chang, F., Li, Z., Duan, C., Sun, X., Wang, S., Wei, D., Li, W., Qian, Y., Cao, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202414961 · Cited by 5
Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis
Moretti, N. R., Kamitani, H. Z., Wagner, P. H. D. S., Matheus, G. T. F. U., Talah, B. A. D., Tanimoto, L. E., Barretto, I. C. D. O., & de Moraes, F. C. A. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04076-9 · Cited by 5
Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6
“Addressing these challenges will require continued innovation in drug design, improved biomarker integration, and more efficient clinical trial frameworks [35].”
Influential
p53 Deficiency-Dependent Oncogenicity of Runx3
Ito, K., Otani, S., & Date, Y. (2023) · Cells · doi:10.3390/cells12081122 · Cited by 6
Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer
Yang, L., Yi, J., He, W., Kong, P., Xie, Q., Jin, Y., Xiong, Z., & Xia, L. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02673-z · Cited by 5
“As TP53 is the most frequently mutated gene in human cancers, gene mutation might cause loss of function of wild-type TP53 [34].”
Role of artificial intelligence in cancer detection using protein p53: A Review
Patil, M. R., & Bihari, A. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10051-4 · Cited by 6
Restoring Tumor Cell Immunogenicity Through Ion‐Assisted p53 mRNA Domestication for Enhanced In Situ Cancer Vaccination Effect
Liang, Y., Zhang, J., Wang, J., Yang, Y. R., Tan, X., Li, S., Guo, Z., Zhang, Z., Liu, J., Shi, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202500825 · Cited by 5
18 F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation
Zheng, W.-J., Xu, Y., Tan, H. S., Chen, S., Wang, P., Sun, H., Li, R., Zeng, H., Zhong, Y.-C., Cheng, J., et al. (2025) · Liver Cancer · doi:10.1159/000544966 · Cited by 5
“These genes are associated with classic tumor suppression ( TP53 [35]), metabolic reprogramming ( B4GALT3 [36] , RXRG [37], SDHC [38]), immune evasion and suppression ( EPPK1 [39], FCGR family [40], and SLAMF7 [41]), and anti-apoptosis ( TP53 [35], MDM4 [42]).”
Mutant p53 confers chemoresistance by activating KMT5B-mediated DNA repair pathway in nasopharyngeal carcinoma
Luo, H., Huang, M.-F., Xu, A., Wang, D., Gingold, J. A., Tu, J., Wang, R., Huo, Z., Chiang, Y.-T., Tsai, K., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217736 · Cited by 6
MIR-4507 Targets TP53 to Facilitate the Malignant Progression of Non‐small‐cell Lung Cancer
Zhao, M., Tang, Z., Wang, Y., Ding, J., Guo, Y., Zhang, N., & Gao, T. (2021) · Journal of Cancer · doi:10.7150/jca.60724 · Cited by 5
“Researchers have found that lung cancer cells experience apoptosis when wild-type TP53 is re-expressed after TP53 mutation or deletion, and clinical trials have confirmed the anti-tumor activity, feasibility, and safety of TP53 gene therapy [21].”
Background
Quantifying Cellular Repair, Misrepair and Apoptosis Induced by Boron Ions, Gamma Rays and PRIMA-1 Using the RHR Formulation
Brahme, A. (2022) · Radiation Research · doi:10.1667/rade-22-00011.1 · Cited by 5
“Furthermore, since the therapeutically active conversion product MQ of PRIMA-1 and APR-246 forms adducts with glutathione (GSH) and decreases cellular GSH and thioredoxin (Trx 1) levels as mentioned in the introduction (16) and seen in Fig.”
Background
Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics
Garg, S., Singh, J., & Verma, S. R. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05454-2 · Cited by 8
“An opportunity to selectively target mutp53 harboring cancer cells is attributable to the structural differences between the wild-type p53 and mutp53 [13, 14].”
Background
Characterization of the interaction between the tumour suppressor p53 and heme and its role in the protein conformational dynamics studied by various spectroscopic techniques and hydrogen/deuterium exchange coupled with mass spectrometry
Vávra, J., Sergunin, A., Pompach, P., Savchenko, D. V., Hraníček, J., Šloufová, I., Shimizu, T., & Martínková, M. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112180 · Cited by 5
PhenoDriver: interpretable framework for studying personalized phenotype-associated driver genes in breast cancer
Li, Y., Zhang, S.-W., Xie, M., & Zhang, T. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad291 · Cited by 5
Altering relative metal-binding affinities in multifunctional Metallochaperones for mutant p53 reactivation
Kwan, K., Castro-Sandoval, O., Ma, B. N., Martelino, D., Saffari, A., Liu, X. L., Orvain, C., Mellitzer, G., Gaiddon, C., & Storr, T. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112433 · Cited by 5
APR-246 enhances the anticancer effect of doxorubicin against p53-mutant AsPC-1 pancreatic cancer cells
Alhammer, A. H., Al-Juboori, S. I. K., & Mudhafar, S. A. (2024) · Baghdad Science Journal · doi:10.21123/bsj.2024.10135 · Cited by 5
“A possible explanation for the mild effect is an increase in the expression of the p53 inhibitor MDM2 in response to a remarkable drug-mediated restoration of the activity of mutated p53 20 .”
Background
Dual amplification dynamic DNA network system for CRISPR/Cas12a based p53 gene detection
Wang, T., Ding, K., Wang, X., Wang, Z., Liu, G., Wang, Z., Lin, S., Zhou, H., & Zang, Y. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.343048 · Cited by 5
Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study
Choi, S., Kim, S. H., Lee, S., Seo, J., Kang, M.-S., Jung, E. H., Kim, S., Suh, K. J., Lee, J. Y., Kim, J., et al. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.046 · Cited by 6
Pestones A and B from a Fungus Pestalotiopsis sp. Bound to Mutant p53 and Changed Its Conformation
Sadahiro, Y., Okubo, M., Hitora, Y., HitoraーImamura, N., Kotani, S., & Tsukamoto, S. (2025) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c01440 · Cited by 5
Loss of p53 protein strikes a nerve to aid tumour growth
Napoli, M., & Flores, E. R. (2020) · Nature · doi:10.1038/d41586-020-00328-6 · Cited by 5
Water-soluble fluorescent copolymer for effective recognition and imaging of tumor
Wei, G., Zhao, G., Lin, N., Guang, S., & Xu, H. (2020) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2020.124863 · Cited by 5
A coordinated ruthenium-rifampicin complex reprogramming the colon carcinoma micro-environment mediated by modulation of p53/AkT/mTOR/VEGF pathway
Zeng, J., Zhao, Y., Li, K., Long, D., Li, W., & Liang, L. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115618 · Cited by 5
Elevated Sodium Pump α3 Subunit Expression Promotes Colorectal Liver Metastasis via the p53-PTEN/IGFBP3-AKT-mTOR Axis
Wu, D., Yu, H., Xiong, H., Zhang, Y., Lin, X., Zhang, J., Wu, W., Wang, T., Liu, X., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.743824 · Cited by 5
“p53 plays a critical role in the regulation of cell migration (34, 34, 38).”
Background
TRPV1 is a potential biomarker for the prediction and treatment of multiple cancers based on a pan-cancer analysis
Huang, T. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022389 · Cited by 5
Identification of immune‐related hub genes and construction of an immune‐related gene prognostic index for low‐grade glioma
Zhou, J., Guo, H., Liu, L., Jin, Z., Zhang, W., & Tang, T. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17960 · Cited by 5
Combined Thermotherapy and Heat Shock Protein Modulation for Tumor Treatment
Hoter, A., Alsantely, A., Alsharaeh, E. H., Kulik, G., & Saadeldin, I. M. (2020) · Heat shock proteins · doi:10.1007/7515_2020_13 · Cited by 5
RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia
Xu, Y., Lin, Y., Luo, Y., Yang, Y., Long, B., Fang, Z., Liu, L., Zhang, J., & Zhang, X. (2020) · Oncology Reports · doi:10.3892/or.2020.7723 · Cited by 5
Anti-pulmonary metastases from cervical cancer responses induced by a human papillomavirus peptide vaccine adjuvanted with CpG-oligodeoxynucleotides in vivo
Suo, J., Yang, Y., Che, Y., Chen, C., Lv, X., & Wang, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107203 · Cited by 5
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
Gillardin, P.-S., Descamps, G., Maïga, S., Tessoulin, B., Djamai, H., Lucani, B., Chiron, D., Moreau, P., Gouill, S. L., Amiot, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010040 · Cited by 4
“RITA and Prima-1Met, which were selected for their ability to induce cell death in p53 mutated cells were shown to bind to p53 protein [9].”
Background
Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73
Wang, Y., Wang, L., Huang, Y., Zhou, L., Li, G., Yang, J., Wu, X.-F., Cheng, J.-C., Xu, Q., & Shen, Y. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01474-1 · Cited by 4
Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia
Hunter, C. J., Im, A., & Shallis, R. M. (2026) · Cancers · doi:10.3390/cancers18020275 · Cited by 5
“TP53 inactivation (via overexpression of MDM2, a negative regulator of TP53 ) or direct mutation impairs these functions, causing unregulated proliferation and immune evasion [6–10].”
PAK1 Inhibition Suppresses the Proliferation, Migration and Invasion of Glioma Cells
Shi, H., Yi, Q., Chen, T., Zhou, K., Ma, Q., & Sun, Z. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203724666221226150329 · Cited by 4
Recent and Advanced Trends in Cancer Treatments
Chithra, R. A., Elamin, M. O., & Karande, S. (2024) · National Journal of Community Medicine · doi:10.55489/njcm.151220244714 · Cited by 4
Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type
Yang, X., Liang, Z., Ji, L., Liu, W., Wang, B., Li, Y., Ou, J.-P., Cen, X., Ren, H., Wuchty, S., et al. (2025) · Human Genomics · doi:10.1186/s40246-025-00792-z · Cited by 5
“Wild-type TP53 acts as a tumor suppressor that induces growth arrest, senescence, apoptosis during cellular stress, while mutant TP53 allows the evasion of tumor cell death and accelerates tumor progression [7].”
Toxicity, Safety, and Pharmacotherapeutic Properties of Ursolic Acid: Current Status, Challenges, and Future Perspectives against Lung Cancer
Subramanian, C., Solairaja, S., Dunna, N. R., & Venkatabalasubramanian, S. (2022) · Current Bioactive Compounds · doi:10.2174/1573407219666221024142326 · Cited by 4
A Pan-Cancer Analysis of Prognostic and Immunological Roles for Cell Death Genes
Hong, Y., Yuan, Y., Liu, Z., Liu, Z., & Zhang, Y. (2023) · Genes · doi:10.3390/genes14061178 · Cited by 4
“TP53 is a well-known tumor-suppressor, while the p53 inactivation caused by TP53 mutations can escape tumor cell death and rapid tumor progression [50].”
Background
Identification of the natural chalcone glycoside hydroxysafflor yellow A as a suppressor of P53 overactivation‐associated hematopoietic defects
Chen, J., Ren, C., Yao, C., Baruscotti, M., Wáng, Y., & Zhao, L. (2023) · MedComm · doi:10.1002/mco2.352 · Cited by 4
TP53 and the Ultimate Biological Optimization Steps of Curative Radiation Oncology
Brahme, A. (2023) · Cancers · doi:10.3390/cancers15174286 · Cited by 4
“Cancers 2023, 15, 4286 21 of 24 Interestingly, PRIMA-1 and APR-246 promote the normal function of a missense mutant p53 protein-increasing LDA and HDA apoptosis in the tumor as well as senescence (Figure 4; [2,7,26–28,35]).”
BackgroundInfluential
An ultrathin Zn-based layered double hydroxides augment degradation of mutant p53 to improve tumor therapy
Qiao, G., Pan, X., He, M., Peng, R., Huang, X., Nie, C., Jiang, J., & Chu, X. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.146449 · Cited by 4
Mutações no gene TP53 e suas implicações em processos de tumorigênese
Martins, A. P., Casali, A. K., & Martins, A. A. S. (2023) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2023v5n5p6304-6321 · Cited by 4
Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions
Naeimzadeh, Y., Tajbakhsh, A., & Fallahi, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26260 · Cited by 5
“Thus, several approaches are available for targeting both wt and mutant p53 to disrupt the formation of aggregation and fibrils for cancer treatment [17,36,99 – 102].”
Method
Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies
Damiani, D., & Tiribelli, M. (2024) · Pharmaceuticals · doi:10.3390/ph17121629 · Cited by 4
A novel compound, SYHA1813, inhibits malignant meningioma growth directly by boosting p53 pathway activation and impairing DNA repair
Lan, Y., Li, S., Wang, J., Yang, X., Wang, C., Huang, M., Zhang, R., Chen, F., & Li, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1522249 · Cited by 4
Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy
Chaudhary, B., Arya, P., Sharma, V., Kumar, P., Singla, D., & Grewal, A. S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108388 · Cited by 5
Targeting the p53/xCT/GSH Axis with PRIMA-1Met Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia
Pasino, M., Speciale, A., Ravera, S., Cutrona, G., Massara, R., Bertola, N., Viale, M., Velkova, I., Mazzarello, A. N., Fais, F., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125559 · Cited by 4
Carfilzomib Induces Drug Resistance in A2780 Ovarian Cancer Cells Through p53-Dependent and Caspase-3 Independent Pathways
Zarei, S., Reza, J. Z., Jaliani, H. Z., Hajizadeh, M. R., & Sargazi, S. (2019) · Journal of Applied Biotechnology Reports · doi:10.29252/jabr.06.02.01 · Cited by 4
Detection of p53 mutation and serum monitoring alert caused by Marek’s disease virus in poultry
Zhang, H., Liu, M., Zhang, H., Cao, S., Li, Y., Jiang, S., Song, Y., & Liu, S. (2020) · BMC Veterinary Research · doi:10.1186/s12917-020-02520-2 · Cited by 4
P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study
Omran, M. M., Fouda, M. S., Abdelwahab, A. O., Nabil, M. M., Abdelaziz, A. O., Omran, D., & Shousha, H. I. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001962 · Cited by 4
Cytologic and Histologic Aspects of High-Grade Transformation of Salivary Gland Carcinoma
Nakaguro, M., Faquin, W. C., & Sadow, P. M. (2020) · AJSP Review and Reports · doi:10.1097/pcr.0000000000000400 · Cited by 4
“p53 is the best-known tumor suppressor, and its encoding gene TP53 is the most frequently mutated gene in cancer.(56) Although strongly positive or negative p53 expression is associated with TP53 mutation,(57) TP53 point mutations have not been commonly detected in HGT cases with p53 overexpression.”
Background
Molecular Prognostic and Predictive Markers in Triple - Negative Breast Cancer
Kolečková, M., Vomáčková, K., & Kolář, Z. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97282 · Cited by 4
“Its product, protein p53, acts as a transcription factor following translocation to the nucleus and has a fundamental influence on the regulation of checkpoints of the cell cycle, cellular response to damaged DNA and telomeres, aerobic cell metabolism, apoptosis, inhibition of angiogenesis and oncogene activation [42].”
Background
Targeted and systemic insights into the crosstalk between DNA-dependent protein kinase catalytic subunit and receptors of estrogen, progesterone and epidermal growth factor in the context of cancer
Ansari, S. M. R., Hijazi, F. S., & Souchelnytskyi, S. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06797-w · Cited by 4
“Inactivating mutations of BRCA1 and TP53 are strongly associated with the promotion of tumorigenesis [40, 41].”
Background
The interaction of p53 and DNA repair gene mutations and their impact on tumor mutation burden and immune response in human malignancies.
Xue, X., Lin, D., Burke, E., Xue, L., & Lu, Y. (2022) · PubMed Central · Cited by 4
Pan-Cancer Analysis of the Roles and Driving Forces of RAB42
Zheng, M., Wang, W., Bu, Y., Liu, J., Ma, J., Wang, R., Ren, X., Lü, Z., Li, J., & Cai, J. (2022) · Biomolecules · doi:10.3390/biom13010043 · Cited by 4
“TP53 is an important tumor suppressor gene and its mutation leads to the rapid progression of many malignancies [46].”
Background
Distinct oncogenic phenotypes in hematopoietic specific deletions of Trp53
Palanichamy, J. K., Tran, T. M., King, J. K., Katzman, S. J., Ritter, A. J., Sharma, G., Tso, C., Contreras, J. R., Fernando, T. R., Sanford, J. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33949-8 · Cited by 4
Artocarpus Communis Seed Regulates P53, IRS, HsD17β2, FTO, and CYP11a Genes in Polycystic Ovarian Syndrome Rats
Ogunlakin, A. D., Ojo, O. A., Onu-Boms, C. D., Afolayan, O. S., Ayeni, P. O., Akinwumi, I. A., Akinmurele, O. J., Alabi, G. O., Ayokunle, D. I., Ambali, O. A., et al. (2024) · OBM Genetics · doi:10.21926/obm.genet.2401213 · Cited by 4
Mis-splicing drives loss of function of p53E224D point mutation
Lock, I. C., Leisenring, N. H., Floyd, W., Xu, E. S., Luo, L., Ma, Y., Mansell, E. C., Cardona, D. M., Lee, C., & Kirsch, D. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318856 · Cited by 3
Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma
Li, J., Liu, X., Qiao, Y., Qi, R., Liu, S.-J., Guo, J., Gui, Y., Li, J., & Yu, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00413 · Cited by 4
“p53 inhibits the occurrence and development of cancer effectively (35).”
Background
Control of Gene Regulatory Networks Basin of Attractions with Batch Reinforcement Learning
Nishida, C. E. H., Costa, A. H. R., & Bianchi, R. A. C. (2018) · Brazilian Conference on Intelligent Systems · doi:10.1109/bracis.2018.00030 · Cited by 4
“[1].”
BackgroundInfluential
Evolutionary genomics of mammalian lung cancer genes reveals signatures of positive selection in APC, RB1 and TP53
Emam, M., Machado, J. P., & Antunes, A. (2020) · Genomics · doi:10.1016/j.ygeno.2020.08.020 · Cited by 4
Co-mutations in tumor immune microenvironment and immunotherapy
Ma, L., Zhu, L., Xu, Z., & Shu, Y. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001455 · Cited by 4
“The tumor suppressor geneTP53 is mutated in around half of all human tumors as the most frequently mutated gene in cancer.([6])Cha et al([7]) found that PD-L1positivity in tumor cells was significantly correlatedwith p53 aberrant expression, PDL1 positivity in tumor-infiltrating immune cells, and higher stage in 323 s…”
Background
A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinomaPreprint
Zhao, W., Kepecs, B., Mahadevan, N. R., Segerstolpe, Å., Weirather, J. L., Besson, N. R., Giotti, B., Soong, B. Y., Li, C., Vigneau, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.28.546977 · Cited by 4
Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma
Sakamoto, Y., Ishida, T., Masaki, A., Murase, T., Ohtsuka, E., Takeshita, M., Muto, R., Choi, I., Iwasaki, H., Ito, A., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03880-3 · Cited by 3
“Additionally, patients with NOTCH1 alterations significantly more frequently harbored TP53 alterations, which might be associated with the contribution of TP53 to genomic stability [39–41].”
Non-oncologic to oncologic drug: A systematic review of drug repurposing in cancer
Dhanush, Y., & Ganesh, V. S. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04822-4 · Cited by 5
Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 ( PDK1 ) to Promote Proliferation and Migration in Breast Cancer
Ye, Y., Ou, Z., Li, C., Liao, Q., Zeng, Q., Ju, X., Zhang, D., Wei, Y., Zhang, X., Zhang, J., et al. (2025) · Cancer Science · doi:10.1111/cas.70252 · Cited by 3
“Stabilization of mutp53 is required for mutp53 GOF in tumorigenesis [49, 57, 58].”
TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study
Zhang, H., Zhang, X., Wang, J., Zhang, X., Lv, Y., Zhu, Y., Ye, X., Wei, J., Yang, M., Xu, G., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06821-8 · Cited by 3
Conjugated Polymer Nanoprobes for NIR-II Imaging-Guided Photodynamic/Photothermal Synergistic Cancer Therapy
Wang, J., Zhang, X., Li, L., Ren, Y., Wang, J., Ma, X., & Tang, Y. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c02462 · Cited by 3
A novel predictive model of microvascular invasion in hepatocellular carcinoma based on differential protein expression
Wang, Z., Cao, L., Wang, J., Wang, H., Ma, T., Yin, Z., Cai, W., Liu, L., Liu, T., Ma, H., et al. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02729-z · Cited by 3
“High expression of P53 is related to the poor prognosis of triple negative breast cancer and ovarian cancer [19].”
Background
Scribble promotes fibrosis-dependent mechanisms of hepatocarcinogenesis by p53/PUMA-mediated glycolysis
Wu, Y., Song, L., Kong, J., Qian, W., Jiao, J., Wang, X., Li, G., Xu, X. D., & Zhan, L. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166823 · Cited by 3
Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth
Lv, F., Zhang, L., Ji, C., Peng, L., Zhu, M., Yang, S., Dong, S., Zhou, M., Guo, F., Li, Z., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108167 · Cited by 3
Nomogram prediction of molecular characteristics in WHO grade 3–4 diffuse gliomas based on fractal analysis and VASARI features
Long, C., Xu, D., Sun, W., Liang, W., Zhou, J., Gui, S., Li, H., & Xu, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-00113-3 · Cited by 3
Leveraging innovative therapies with an evolving understanding of the molecular pathogenesis of penile squamous cell carcinoma
Hajiran, A. J., Bracco, T., Zemp, L. W., & Spiess, P. E. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.06.024 · Cited by 3
Molecular and therapeutic bases of cancer
Fajardo-Orduña, G. R., & Chamorro-Plata, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819828-5.00002-4 · Cited by 3
Improving Reporter Gene Assay Methodology for Evaluating the Ability of Compounds to Restore P53 Activity
Han, X., Du, J., Shi, D., Li, L., Li, D., Zhang, K., Lin, S.-W., Zhu, J., Huang, Z., Zhou, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213867 · Cited by 3
“Furthermore, some mutant P53 proteins could acquire new oncogenic properties called gain of function (GOF) [10].”
Background
Evaluation of Novel Enhancer Compounds in Gentamicin-Mediated Readthrough of Nonsense Mutations in Rett Syndrome
Wong, K. M., Wegener, E., Baradaran‐Heravi, A., Huppke, B., Gärtner, J., & Huppke, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411665 · Cited by 3
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53
Siddon, A. J., & Weinberg, O. K. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.07.004 · Cited by 3
The Correlation Study between TP53 Gene Expression and Acute Myeloid Leukemia in Iraq
Dawood, H. H., & Mohammed, R. K. (2023) · Iraqi Journal of Science · doi:10.24996/ijs.2023.64.11.14 · Cited by 3
“As a result, defects in the p53 protein's function are expected by mutations of this “guardian of the genome,” allowing cells to be underlying for programmed cell death (apoptosis) to avoid it and promote the development of cancerous diseases [5, 6].”
Background
Single‐cell and bulk RNA‐sequencing reveals mitosis‐involved gene HAUS1 is a promising indicator for predicting prognosis and immune responses in prostate adenocarcinoma (PRAD)
Liu, S., Yu, Y., Xu, J., Wang, Y., & Li, D. (2024) · Cell Biology International · doi:10.1002/cbin.12191 · Cited by 3
“However, in the study of various malignant tumors, these pathways were often mutated, which prevented these giant cells from being killed (Bykov et al., 2018).”
Network pharmacology and metabolomics elucidate the underlying effects and mechanisms of maackiain against endometrial cancer
Xing, Y., Wang, W., Cheng, Y., Hu, D., Du, J., He, R., Lv, X., & Yang, Y. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151119 · Cited by 3
Deregulation mechanisms and therapeutic opportunities of p53-responsive microRNAs in diffuse large B-cell lymphoma
Voropaeva, E. N., Orlov, Y. L., Loginova, A. B., Seregina, O. B., Maximov, V. N., & Pospelova, T. I. (2025) · PeerJ · doi:10.7717/peerj.18661 · Cited by 5
Molecular genetic signatures of head and neck squamous cell carcinoma and their changes induced by proton irradiation
Jumaniyazova, E. D., Sentyabreva, A. V., Kosyreva, A. M., & Lokhonina, А. V. (2024) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2024-28-4-413-426 · Cited by 3
Sinusoidal rhythm caused by fetal hemorrhage during fetoscopy.
Nicolini, U., Hertogs, K., & Rodeck, C. H. (1984) · PubMed · Cited by 3
Genome-wide CRISPR screens reveal APR-246 (Eprenetapopt) triggers ferroptosis and inhibits iron-sulfur cluster biogenesisPreprint
Fujihara, K. M., Zhang, B., Jackson, T. D., Nijiagel, B., Ang, C., Nikolić, I., Sutton, V. R., Trapani, J., Simpson, K. J., Stojanovski, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.29.398867 · Cited by 3
A Water‐Stable and Red‐Emissive Radical Cation for Mutp53 Cancer Therapy
Zhou, Z., Qian, J., Liu, K., Zhang, Y., Gao, M., & Tang, B. Z. (2022) · Angewandte Chemie · doi:10.1002/ange.202212671 · Cited by 2

Authors: Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G.
Affiliations: Karolinska Institutet (SE)
Corresponding author: Wiman, Klas G.
ORCID: Bykov, Vladimir J. N.
Eriksson, Sofi E.
Bianchi, Julie
Wiman, Klas G.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2017-12-15
Volume: 18
Issue: 2
Pages: 89-102
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc.2017.109
OpenAlex: W2772062014
Cited by: 889
References: 159
Citations by year: 2026: 43 · 2025: 70 · 2024: 100 · 2023: 132 · 2022: 126 · 2021: 150 · 2020: 129 · 2019: 88 · 2018: 49 · 2017: 1
FWCI: 7.67
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords: TP53, mutant p53, p53 reactivation, missense mutations, nonsense mutation, tumor suppressor, cancer therapy, cancer cell death, clinical trials
MeSH terms: Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Tumor Suppressor Protein p53, Cell Death, Mutant Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting mutant p53 for efficient cancer therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks